Pancreatic Cancer Research

ResearcherOsaka International Cancer InstituteActive in the last 2 years

Hiroshi Wada

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0510-5744; OpenAlex author ID A5032551332. Sources: OpenAlex.

Their work

Papers
7 (first author 0, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
23
Papers, trials and grants by year

2023: 1 paper · 2024: 2 papers · 2025: 3 papers · 2026: 1 paper

Papers 7

  1. Study protocol: A randomized controlled trial of chemoradiotherapy versus chemotherapy as neoadjuvant therapy for resectable pancreatic cancer (CSGO-HBP-027). Co-author DOI 10.1371/journal.pone.0345459↗
  2. Response to letter to the editor: "A striking elevation of CA19-9 after preoperative therapy negates prognostic benefit from radical surgery in resectable or b… Last author DOI 10.1016/j.surg.2024.109053↗
  3. Reply to letter to editor by yinfang Wu, MM about our manuscript, "A striking elevation of CA19-9 after preoperative therapy negates prognostic benefit from ra… Last author DOI 10.1016/j.surg.2024.109132↗
  4. Reply to letter to editor by Duo Yun, MD regarding our article, "A striking elevation of CA19-9 after preoperative therapy negates prognostic benefit from radi… Last author DOI 10.1016/j.surg.2024.11.003↗
  5. Prognostic impact of aberrant right hepatic artery involvement in patients with pancreatic cancer: A multicenter retrospective cohort study. Co-author DOI 10.1002/jso.27792↗
  6. A striking elevation of CA19-9 after preoperative therapy negates prognostic benefit from radical surgery in resectable and borderline resectable pancreatic ca… Last author DOI 10.1016/j.surg.2024.06.049↗
  7. Pathological Nodal and Vascular Involvement Significantly Impacts the Recurrence Risk in Different Time Frames in Patients With Resectable and Borderline Resec… Co-author DOI 10.1097/sla.0000000000005879↗

Closest collaborators

The 23 strongest of 23 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hirofumi Akita · 7 shared papers, 2023–2026 · strength 1.85
  2. Masahiko Kubo · 5 shared papers, 2024–2025 · strength 1.43
  3. Yosuke Mukai · 4 shared papers, 2024–2025 · strength 1.27
  4. Hidetoshi Eguchi · 3 shared papers, 2023–2026 · strength 0.58
  5. Hidenori Takahashi · 3 shared papers, 2023–2024 · strength 0.53
  6. Tadafumi Asaoka · 2 shared papers, 2024–2026 · strength 0.39
  7. Yuichiro Doki · 2 shared papers, 2024–2026 · strength 0.39
  8. Yoshifumi Iwagami · 2 shared papers, 2024–2026 · strength 0.39
  9. Yoshito Tomimaru · 2 shared papers, 2024–2026 · strength 0.39
  10. Shinichiro Hasegawa · 2 shared papers, 2024 · strength 0.33
  11. Chikato Koga · 1 shared paper, 2026 · strength 0.22
  12. Masahiro Tanemura · 1 shared paper, 2026 · strength 0.22
  13. Masahiro Murakami · 1 shared paper, 2026 · strength 0.22
  14. Masanori Tsujie · 1 shared paper, 2026 · strength 0.22
  15. Yoshiteru Katsura · 1 shared paper, 2026 · strength 0.22
  16. Hiroaki Ohigashi · 1 shared paper, 2023 · strength 0.19
  17. Masato Sakon · 1 shared paper, 2023 · strength 0.19
  18. Osamu Ishikawa · 1 shared paper, 2023 · strength 0.19
  19. Reishi Toshiyama · 1 shared paper, 2024 · strength 0.17
  20. Daisaku Yamada · 1 shared paper, 2024 · strength 0.17
  21. Kunihito Gotoh · 1 shared paper, 2024 · strength 0.17
  22. Hiroki Ueda · 1 shared paper, 2024 · strength 0.17
  23. Kazuki Sasaki · 1 shared paper, 2024 · strength 0.17

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.